The different doses were determined following previous published results on other cancer cell lines [40,41] and by treating GSCs #1 and #83 with Digoxin from 50 to 200 nM and with Acriflavine from 2.5 to 10 μM and measuring HIF-1α expression as shown in Supplementary Figure S1. The gene discussed is HIF1A; the disease is cancer.